Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
This disclosure relates to mRNA therapy for the treatment of hyperphenylalaninemias such as phenylketonuria (PKU). mRNAs for use in the invention, when administered in vivo, encode human phenylalanine hydroxylase (PAH), functional fragments thereof (e.g., those comprising the catalytic domain or the catalytic domain and the tetramerization domains), and fusion proteins comprising PAH. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of PAH expression and/or activity in subjects. mRNA therapies of the invention further decrease abnormal accumulation of phenylalanine associated with deficient PAH activity in subjects.
1. A method of treating phenylketonuria in a human subject that has phenylketonuria, comprising administering to the human subject an effective amount of a pharmaceutical composition comprising a lipid nanoparticle comprising
or a salt thereof, wherein the pharmaceutical composition comprises an mRNA comprising an open reading frame encoding a phenylalanine hydroxylase polypeptide.
2. The method of claim 1 , wherein the lipid nanoparticle further comprises a phospholipid, a structural lipid, and a PEG-modified lipid.
3. The method of claim 1 , wherein the administration to the human subject is about once a week, about once every two weeks, or about once a month.
4. The method of claim 1 , wherein the pharmaceutical composition is administered intravenously.
5. The method of claim 1 , wherein the pharmaceutical composition is administered subcutaneously.
6. The method of claim 2 , wherein the phospholipid is 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) or 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), wherein the structural lipid is cholesterol, and wherein the PEG-modified lipid is PEG-DMG or
7. The method of claim 2 , wherein the phospholipid is DSPC, wherein the structural lipid is cholesterol, and wherein the PEG-modified lipid is Compound I.
8. The method of claim 6 , wherein the administration to the human subject is about once a week, about once every two weeks, or about once a month.
9. The method of claim 6 , wherein the pharmaceutical composition is administered intravenously.
10. The method of claim 6 , wherein the pharmaceutical composition is administered subcutaneously.
11. The method of claim 3 , wherein the pharmaceutical composition is administered intravenously.
12. The method of claim 3 , wherein the pharmaceutical composition is administered subcutaneously.
13. The method of claim 8 , wherein the pharmaceutical composition is administered intravenously.
14. The method of claim 8 , wherein the pharmaceutical composition is administered subcutaneously.
15. The method of claim 7 , wherein the administration to the human subject is about once a week, about once every two weeks, or about once a month.
16. The method of claim 7 , wherein the pharmaceutical composition is administered intravenously.
17. The method of claim 7 , wherein the pharmaceutical composition is administered subcutaneously.
18. The method of claim 15 , wherein the pharmaceutical composition is administered intravenously.
19. The method of claim 15 , wherein the pharmaceutical composition is administered subcutaneously.